AcuamarkDx

New York, United States Founded: 2013 • Age: 13 yrs
Non-invasive screening tests for early cancer detection are provided.
Request Access

About AcuamarkDx

AcuamarkDx is a company based in New York (United States) founded in 2013.. AcuamarkDx has raised $20.01 million across 4 funding rounds from investors including Bruker and Claudio Del Vecchio. AcuamarkDx offers products and services including qPCR Cancer Assay. AcuamarkDx operates in a competitive market with competitors including Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.

  • Headquarter New York, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Acuamark Diagnostics, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $20.01 M (USD)

    in 4 rounds

  • Latest Funding Round
    $4.94 M (USD), Series A

    May 22, 2024

  • Investors
    Bruker

    & 1 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of AcuamarkDx

AcuamarkDx offers a comprehensive portfolio of products and services, including qPCR Cancer Assay. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Technology for detecting early-stage cancer markers in blood samples.

Funding Insights of AcuamarkDx

AcuamarkDx has successfully raised a total of $20.01M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $4.94 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series A — $4.9M
  • First Round

    (16 Nov 2016)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2024 Amount Series A - AcuamarkDx Valuation

investors

Jul, 2022 Amount Series A - AcuamarkDx Valuation Claudio Del Vecchio
Sep, 2019 Amount Seed - AcuamarkDx Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in AcuamarkDx

AcuamarkDx has secured backing from 2 investors, including angel and institutional investors. Prominent investors backing the company include Bruker and Claudio Del Vecchio. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Angel
Investor Description Founded Year Domain Location
Diversified research instrument systems are manufactured and supplied.
Founded Year Domain Location

Claudio Del Vecchio

-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by AcuamarkDx

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - AcuamarkDx

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Acuamarkdx Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of AcuamarkDx

AcuamarkDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
Circulating tumor DNA is screened for early cancer detection.
domain founded_year HQ Location
Provider of DNA sequencing for cancer detection
domain founded_year HQ Location
Provider of cell-free cancer liquid biopsy test
domain founded_year HQ Location
Blood-based liquid biopsy tests for multiple cancer detection are provided.
domain founded_year HQ Location
MicroRNA profiling platform is developed to detect genes in samples.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Acuamarkdx

Frequently Asked Questions about AcuamarkDx

When was AcuamarkDx founded?

AcuamarkDx was founded in 2013 and raised its 1st funding round 3 years after it was founded.

Where is AcuamarkDx located?

AcuamarkDx is headquartered in New York, United States. It is registered at New York, New York, United States.

Is AcuamarkDx a funded company?

AcuamarkDx is a funded company, having raised a total of $20.01M across 4 funding rounds to date. The company's 1st funding round was a Seed of $2.29M, raised on Nov 16, 2016.

What does AcuamarkDx do?

Provider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first application is colorectal cancer, but the company plans to expand to a pan-cancer assay.

Who are the top competitors of AcuamarkDx?

AcuamarkDx's top competitors include Guardant Health, GRAIL and BillionToOne.

What products or services does AcuamarkDx offer?

AcuamarkDx offers qPCR Cancer Assay.

Who are AcuamarkDx's investors?

AcuamarkDx has 2 investors. Key investors include Bruker, and Claudio Del Vecchio.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available